A Comparative Clinical Study of Shigru Kwatha and Livogrit in Yakritvikara (Non Alcholic Fatty Liver Disease)

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan1 个研究点分布在 1 个国家目标入组 40 人开始时间: 2023年10月15日最近更新: 2023年5月10日

试验速览

阶段: 2/3 期
状态: 尚未招募
发起方
入组人数: 40
试验地点: 1
主要终点: Subjective criteria

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a open label double arm comparative study , comparing the efficacy of Shigru Kwatha 100 ml twice daily before meal and Livogrit tablet each 500mg 2 tablet twice daily before meal in 40 patients with Yakritvikara that will be conducted in OPD no. 13/14 in Patanjali Ayurvedic hospital, Haridwar. Assessment will be done on the basis of subjective and objective parameter.

Route of administration- Oral Route

Follow up- follow up will be done to observe effects of treatment or any adverse effect on the patient.

研究设计

研究类型: Interventional
分配方式: Not Applicable
盲法: Open Label

入排标准

年龄范围: 18.00 Year(s) 至 65.00 Year(s)（—）
性别: All

入选标准

•Patient between the age group of 18 to 65 years will be selected.
•Patient irrespective of gender, religion, occupation and chronicity will be selected for the study.
•Both fresh and treated cases would be taken for the study.
•Patient with Grade 1 and Grade 2 fatty liver only will be selected for the study.
•Individual with controlled Diabetes Mellitus having Grade 1 and Grade 2 fatty liver will be selected for the study.

排除标准

•1.Pregnant or lactating women will be excluded.
•Patient who have had Hepatitis B,C or other hepatic viral infection , autoimmune hepatitis and drug induced hepatitis or alcoholic hepatitis will be excluded.
•Patient with severe complication of the cardiovascular, renal or hematopoietic systems and mental disease will be excluded.
•Patient will be excluded having decompensated liver disease.
•Patient with prolonged or a history of ascites , developed Hepatocellular carcinoma Hepatic Encephalopathy , Variceal bleeding will be excluded.
•Patient with a history of using IFN or antiviral agents or Corticosteroids or Immunosuppresive drugs will also be excluded.